Rejected at 9:29 p.m. Oct, 31, 2023 ] by dollajas
Author: harmorgmed
Related Note: 1462913711724
Rationale for change

"𝛂" is how the enzyme is usually referred to (see First Aid image)

Rejection reason

comments. agree with leaving it as alpha in this case since it is a drug name and not a receptor

Text Text
Extra
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Sketchy
Sketchy 2
Empty field
Sketchy Extra
Picmonic
Empty field
Pixorize
Physeo
Bootcamp
OME
Additional Resources
Empty field
One by one
Empty field
#PANCE::ENDO::diabetes #AK_Step1_v12::#OME::PreClinical::04_Organ_Systems::06_Endocrine::05_Pancreas::03_Diabetes_Pharmacology #AK_Step1_v12::#AMBOSS::LWawNj #AK_Step1_v12::#SketchyPharm::05_GI_&_Endocrine::06_Retired_Lessons::03_Metformin,_thiazolidinediones,_pramlintide,_SGLT2_inhibitors_[Retired_Video] #AK_Step1_v12::#Low/HighYield::2-RelativelyHighYield #AK_Step1_v12::#DirtyMedicine::05_Pharmacology::15_Diabetes_Drugs_(Oral_Antihyperglycemics_&_Insulins) #AK_Step1_v12::#SketchyPharm::05_GI_&_Endocrine::02_Diabetes::02_Metformin,_Thiazolidinediones,_Pramlintide,_SGLT2_Inhibitors #AK_Other::#AK_Original_Decks::Step_1::Zanki_Pharmacology #AK_Step1_v12::#Bootcamp::Endocrinology::07_Pancreas::09_Diabetes_Type_2_Management #AK_Step1_v12::#OME::04_Organ_Systems::06_Endocrine::05_Pancreas::03_Diabetes_Pharmacology #AK_Step1_v12::#B&B::09_Endocrinology::03_Pancreas::06_Treatment_of_Diabetes_Mellitus::Extra #AK_Step1_v12::#Pixorize::03_Pharmacology::07_Diabetes_Drugs_(New)::10_Alpha-Glucosidase_Inhibitors #AK_Step1_v12::#FirstAid::08_Endocrine::05_Pharm::01_Diabetes_mellitus_therapy::*Alpha-Glucosidase_Inhibitors #AK_Step1_v12::#Pixorize::03_Pharmacology::08_Diabetes_Drugs_(Old)::09_alpha-Glucosidase_Inhibitors #AK_Step1_v12::#Physeo::09_Pharm::07_Endocrine::08_Alpha-Glucosidase_Inhibitors #PANCE::EOR::PEDS #AK_Other::Only_Step_1 #AK_Step1_v12::#Physeo::^physeo_image_update #AK_Step1_v12::^Systems::Endocrine::Pharmacology